Sökning: onr:"swepub:oai:DiVA.org:umu-49267" > Delivering affordab...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04562naa a2200709 4500 | |
001 | oai:DiVA.org:umu-49267 | |
003 | SwePub | |
008 | 111104s2011 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-492672 URI |
024 | 7 | a https://doi.org/10.1016/S1470-2045(11)70141-32 DOI |
040 | a (SwePub)umu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Sullivan, Richard4 aut |
245 | 1 0 | a Delivering affordable cancer care in high-income countries |
264 | 1 | a London :b Lancet Oncology,c 2011 |
338 | a print2 rdacarrier | |
520 | a The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of cancer due to premature death and disability (not including direct medical costs) was estimated to be US$895 billion. This is not simply due to an increase in absolute numbers, but also the rate of increase of expenditure on cancer. What are the drivers and solutions to the so-called cancer-cost curve in developed countries? How are we going to afford to deliver high quality and equitable care? Here, expert opinion from health-care professionals, policy makers, and cancer survivors has been gathered to address the barriers and solutions to delivering affordable cancer care. Although many of the drivers and themes are specific to a particular field-eg, the huge development costs for cancer medicines-there is strong concordance running through each contribution. Several drivers of cost, such as over-use, rapid expansion, and shortening life cycles of cancer technologies (such as medicines and imaging modalities), and the lack of suitable clinical research and integrated health economic studies, have converged with more defensive medical practice, a less informed regulatory system, a lack of evidence-based sociopolitical debate, and a declining degree of fairness for all patients with cancer. Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system. A radical shift in cancer policy is also required. Political toleration of unfairness in access to affordable cancer treatment is unacceptable. The cancer profession and industry should take responsibility and not accept a substandard evidence base and an ethos of very small benefit at whatever cost; rather, we need delivery of fair prices and real value from new technologies. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Peppercorn, Jeffrey4 aut |
700 | 1 | a Sikora, Karol4 aut |
700 | 1 | a Zalcberg, John4 aut |
700 | 1 | a Meropol, Neal J.4 aut |
700 | 1 | a Amir, Eitan4 aut |
700 | 1 | a Khayat, David4 aut |
700 | 1 | a Boyle, Peter4 aut |
700 | 1 | a Autier, Philippe4 aut |
700 | 1 | a Tannock, Ian F.4 aut |
700 | 1 | a Fojo, Tito4 aut |
700 | 1 | a Siderov, Jim4 aut |
700 | 1 | a Williamson, Steve4 aut |
700 | 1 | a Camporesi, Silvia4 aut |
700 | 1 | a McVie, J. Gordon4 aut |
700 | 1 | a Purushotham, Arnie D.4 aut |
700 | 1 | a Naredi, Peter,d 1955-u Umeå universitet,Kirurgi4 aut0 (Swepub:umu)pena0001 |
700 | 1 | a Eggermont, Alexander4 aut |
700 | 1 | a Brennan, Murray F.4 aut |
700 | 1 | a Steinberg, Michael L.4 aut |
700 | 1 | a De Ridder, Mark4 aut |
700 | 1 | a McCloskey, Susan A.4 aut |
700 | 1 | a Verellen, Dirk4 aut |
700 | 1 | a Roberts, Terence4 aut |
700 | 1 | a Storme, Guy4 aut |
700 | 1 | a Hicks, Rodney J.4 aut |
700 | 1 | a Ell, Peter J.4 aut |
700 | 1 | a Hirsch, Bradford R.4 aut |
700 | 1 | a Carbone, David P.4 aut |
700 | 1 | a Schulman, Kevin A.4 aut |
700 | 1 | a Catchpole, Paul4 aut |
700 | 1 | a Taylor, David4 aut |
700 | 1 | a Geissler, Jan4 aut |
700 | 1 | a Brinker, Nancy G.4 aut |
700 | 1 | a Meltzer, David4 aut |
700 | 1 | a Kerr, David4 aut |
700 | 1 | a Aapro, Matti4 aut |
710 | 2 | a Umeå universitetb Kirurgi4 org |
773 | 0 | t The Lancet Oncologyd London : Lancet Oncologyg 12:10, s. 933-980q 12:10<933-980x 1470-2045x 1474-5488 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-49267 |
856 | 4 8 | u https://doi.org/10.1016/S1470-2045(11)70141-3 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.